CompletedNCT01114308
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Los Angeles and 19 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 287
- Sponsor
- Titan Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01114308
- Official title
Show the full official title
A Randomized, Placebo and Active-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence
Recruitment & locations
CompletedLos Angeles · National City · Oceanside
16 more locations
- Torrance
- Jacksonville
- Largo
- Lauderhill
- North Miami
- Baltimore
- Fall River
- Flowood
- St Louis
- New York
- Durham
- Cincinnati
- Philadelphia
- Charleston
- Burlington
- Everett
Questions about this study
Who is behind this study?
The study sponsor is Titan Pharmaceuticals.
Did this study involve medication?
Yes. The study involved medication, including Probuphine (buprenorphine implant), placebo implant and Buprenorphine.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me